Top positive review
Good insights on wrong doings of Ranbaxy
26 May 2019
This is well supported by facts but in many ways it is biased towards Indian generics. Ranbaxy may have followed malpractices as written in this book but all generics are not same in practices. Even US too has generic manufacturers, there is no mention about these companies.
Another important understanding of Ranbaxy ways of working under the leadership of Malwinder Singh & team is that, the behaviour was driven by Profits over and above Purpose, which was fueled by policies of US like F2F and exclusivity with bare minimum checks.
There could be few isolated issues of generics not matching bioequivalence of innovator drug but it may not be case that generic manufacturer has deliberately followed some shortcut. Even sometimes innovator drugs are pulled off shelves for not meeting desired results.